(Reuters) - Catalent has agreed to sell its oral drug development and small-scale manufacturing facility in Somerset, New ...

Catalent, Inc. (NYSE: CTLT), the leader in enabling the development and supply of better treatments for patients worldwide, ...

Somerset facility State-of-the art facility for clinical and commercial manufacturing of oral dosage forms. Ghent, Belgium, ...

Catalent (NYSE:CTLT) is selling its oral solids development and small-scale manufacturing facility in Somerset, New Jersey to ...

The site also serves as an oral solids development and small-scale manufacturing facility for the pharmaceutical company, ...

Sen. Elizabeth Warren urges FTC to scrutinize Novo Nordisk's $16.5 billion acquisition of Catalent over concerns of increased ...

NEW YORK (Reuters) -U.S. Senator Elizabeth Warren has asked antitrust regulators to scrutinize a $16.5 billion deal in which ...

Awaiting a potential acquisition by Novo Holdings, Catalent is giving its contract manufacturing compatriot a boost as Ardena ...

Catalent entered into a definitive agreement to sell its oral solids development and small-scale manufacturing facility in ...

On Monday, Catalent Inc (CTLT) stock saw a modest uptick, ending the day at $60.65 which represents a slight increase of $0.20 or 0.33% from the prior close of $60.45. The stock opened at $60.5 and ...

Catalent, Inc. (CTLT), a provider of advanced delivery technologies and development solutions for drugs, biologics, and consumer ...

Senator Elizabeth Warren told the Federal Trade Commission that the acquisition of contract manufacturer Catalent could ...